A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP (NCT04850118)

🧪 Interventions in This Study

• rAAV2tYF-GRK1-hRPGRco (BIOLOGICAL)
• Control (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (25 Sites)

• Retina Macula Institute of Arizona — Scottsdale, Arizona
• Children's Hospital Los Angeles — Los Angeles, California
• University of Florida Health Jacksonville, Department of Ophthalmology — Jacksonville, Florida
• Bascom Palmer Eye Institute- University of Miami — Miami, Florida
• Midwest Eye Institute (Retina Partners Midwest) — Carmel, Indiana
• Wilmer Eye Institute at Johns Hopkins — Baltimore, Maryland
• Ophthalmic Consultants of Boston — Boston, Massachusetts
• Mayo Clinic — Rochester, Minnesota
• Duke Eye Center — Durham, North Carolina
• Cincinnati Eye Institute — Cincinnati, Ohio
• Cole Eye Institute - Cleveland Clinic — Cleveland, Ohio
• Casey Eye Institute, OHSU — Portland, Oregon
• The Center for Advanced Retinal & Ocular Therapeutics University of Pennsylvania Perelman School of Medicine — Philadelphia, Pennsylvania
• Mid Atlantic Retina — Philadelphia, Pennsylvania
• University of Pittsburgh — Pittsburgh, Pennsylvania
• Retina Consultants of Texas — Bellaire, Texas
• Retina Foundation of the Southwest — Dallas, Texas
• Baylor Eye Institute — Houston, Texas
• Retina Consultants of San Antonio Texas — San Antonio, Texas
• Sydney Eye Hospital — Sydney, New South Wales
• Royal Victorian Eye & Ear Hospital — East Melbourne, Victoria
• McGill University Health Centre - Glen Site — Montreal, Quebec
• Moorfields Eye Hospital — London,
• The Retina Clinic London, Institute of Ophthalmology, University College London — London,
• Oxford Eye Hospital — Oxford,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in X-Linked Retinitis Pigmentosa

• Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations — Durham, North Carolina
• Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene — La Jolla, California
• A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP) — Boston, Massachusetts
• A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) — Jacksonville, Florida
• 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) — Aurora, Colorado

Explore by condition: All X-Linked Retinitis Pigmentosa clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.